152 related articles for article (PubMed ID: 31958984)
61. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
[TBL] [Abstract][Full Text] [Related]
62. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
[TBL] [Abstract][Full Text] [Related]
63. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.
Li J; Knoll S; Bocharova I; Tang W; Signorovitch J
Curr Med Res Opin; 2019 Jan; 35(1):105-111. PubMed ID: 30362839
[No Abstract] [Full Text] [Related]
64. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
65. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ
Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318
[TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
Limwattananon C; Limwattananon S; Waleekhachonloet O; Rattanachotphanit T
Lung Cancer; 2018 Jun; 120():91-97. PubMed ID: 29748023
[TBL] [Abstract][Full Text] [Related]
67. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
[TBL] [Abstract][Full Text] [Related]
69. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
70. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
[TBL] [Abstract][Full Text] [Related]
71. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
Zhang C; Li SL; Nie Q; Dong S; Shao Y; Yang XN; Wu YL; Yang Y; Zhong WZ
J Thorac Oncol; 2019 Apr; 14(4):726-731. PubMed ID: 30408570
[TBL] [Abstract][Full Text] [Related]
72. Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.
Ma D; Zhang Y; Xing P; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang H; Du Y; Zhang Z; Liang L; Li J
Thorac Cancer; 2019 May; 10(5):1213-1219. PubMed ID: 30993895
[TBL] [Abstract][Full Text] [Related]
73. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
74. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
[TBL] [Abstract][Full Text] [Related]
75. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
76. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
[TBL] [Abstract][Full Text] [Related]
77. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
78. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
[TBL] [Abstract][Full Text] [Related]
79. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
[TBL] [Abstract][Full Text] [Related]
80. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
